Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus-A case report

Abhijeet Danve, Lisa Perry, Atulya (Atul) Deodhar

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Pregnancy can lead to flares in systemic lupus erythematosus (SLE), and the presence of SLE in pregnancy could lead to a poor outcome for the mother and the fetus. Objective: To describe a patient whose active SLE (including lupus nephritis) was managed with the use of belimumab throughout pregnancy. Methods: A case report and review of relevant literature is presented. Results: A 38-year-old Caucasian woman with SLE was seen for advice regarding planning a pregnancy and management of her active lupus (cutaneous lupus, angioedema, lupus nephritis, leukopenia, and anti-phospholipid antibody syndrome) that could only be controlled by mycophenolate, a drug contraindicated in pregnancy. Azathioprine, hydroxychloroquine, rituximab, and moderate doses of prednisone were either unable to control her disease or led to unacceptable toxicity. After detailed discussions, she was treated with belimumab, which controlled her SLE and allowed withdrawal of mycophenolate. Belimumab was continued throughout the pregnancy, leading to well-controlled SLE and uneventful course, albeit with the presence of mild Ebstein's anomaly in the baby. Conclusion: To our knowledge, this is the first case report of belimumab use throughout pregnancy for controlling active SLE. Data from the belimumab pregnancy registry would be useful to confirm our findings and to further assess safety of this agent for use in pregnancy.

Original languageEnglish (US)
Pages (from-to)195-197
Number of pages3
JournalSeminars in Arthritis and Rheumatism
Volume44
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Systemic Lupus Erythematosus
Pregnancy
Lupus Nephritis
Ebstein Anomaly
Hydroxychloroquine
belimumab
Angioedema
Antiphospholipid Syndrome
Azathioprine
Leukopenia
Prednisone
Registries
Fetus
Mothers
Safety
Skin
Pharmaceutical Preparations

Keywords

  • Belimumab
  • Lupus
  • Lupus nephritis
  • Pregnancy
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Anesthesiology and Pain Medicine
  • Medicine(all)

Cite this

Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus-A case report. / Danve, Abhijeet; Perry, Lisa; Deodhar, Atulya (Atul).

In: Seminars in Arthritis and Rheumatism, Vol. 44, No. 2, 2015, p. 195-197.

Research output: Contribution to journalArticle

@article{3f1977abf7a346ae983311276858581b,
title = "Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus-A case report",
abstract = "Background: Pregnancy can lead to flares in systemic lupus erythematosus (SLE), and the presence of SLE in pregnancy could lead to a poor outcome for the mother and the fetus. Objective: To describe a patient whose active SLE (including lupus nephritis) was managed with the use of belimumab throughout pregnancy. Methods: A case report and review of relevant literature is presented. Results: A 38-year-old Caucasian woman with SLE was seen for advice regarding planning a pregnancy and management of her active lupus (cutaneous lupus, angioedema, lupus nephritis, leukopenia, and anti-phospholipid antibody syndrome) that could only be controlled by mycophenolate, a drug contraindicated in pregnancy. Azathioprine, hydroxychloroquine, rituximab, and moderate doses of prednisone were either unable to control her disease or led to unacceptable toxicity. After detailed discussions, she was treated with belimumab, which controlled her SLE and allowed withdrawal of mycophenolate. Belimumab was continued throughout the pregnancy, leading to well-controlled SLE and uneventful course, albeit with the presence of mild Ebstein's anomaly in the baby. Conclusion: To our knowledge, this is the first case report of belimumab use throughout pregnancy for controlling active SLE. Data from the belimumab pregnancy registry would be useful to confirm our findings and to further assess safety of this agent for use in pregnancy.",
keywords = "Belimumab, Lupus, Lupus nephritis, Pregnancy, Systemic lupus erythematosus",
author = "Abhijeet Danve and Lisa Perry and Deodhar, {Atulya (Atul)}",
year = "2015",
doi = "10.1016/j.semarthrit.2014.05.006",
language = "English (US)",
volume = "44",
pages = "195--197",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus-A case report

AU - Danve, Abhijeet

AU - Perry, Lisa

AU - Deodhar, Atulya (Atul)

PY - 2015

Y1 - 2015

N2 - Background: Pregnancy can lead to flares in systemic lupus erythematosus (SLE), and the presence of SLE in pregnancy could lead to a poor outcome for the mother and the fetus. Objective: To describe a patient whose active SLE (including lupus nephritis) was managed with the use of belimumab throughout pregnancy. Methods: A case report and review of relevant literature is presented. Results: A 38-year-old Caucasian woman with SLE was seen for advice regarding planning a pregnancy and management of her active lupus (cutaneous lupus, angioedema, lupus nephritis, leukopenia, and anti-phospholipid antibody syndrome) that could only be controlled by mycophenolate, a drug contraindicated in pregnancy. Azathioprine, hydroxychloroquine, rituximab, and moderate doses of prednisone were either unable to control her disease or led to unacceptable toxicity. After detailed discussions, she was treated with belimumab, which controlled her SLE and allowed withdrawal of mycophenolate. Belimumab was continued throughout the pregnancy, leading to well-controlled SLE and uneventful course, albeit with the presence of mild Ebstein's anomaly in the baby. Conclusion: To our knowledge, this is the first case report of belimumab use throughout pregnancy for controlling active SLE. Data from the belimumab pregnancy registry would be useful to confirm our findings and to further assess safety of this agent for use in pregnancy.

AB - Background: Pregnancy can lead to flares in systemic lupus erythematosus (SLE), and the presence of SLE in pregnancy could lead to a poor outcome for the mother and the fetus. Objective: To describe a patient whose active SLE (including lupus nephritis) was managed with the use of belimumab throughout pregnancy. Methods: A case report and review of relevant literature is presented. Results: A 38-year-old Caucasian woman with SLE was seen for advice regarding planning a pregnancy and management of her active lupus (cutaneous lupus, angioedema, lupus nephritis, leukopenia, and anti-phospholipid antibody syndrome) that could only be controlled by mycophenolate, a drug contraindicated in pregnancy. Azathioprine, hydroxychloroquine, rituximab, and moderate doses of prednisone were either unable to control her disease or led to unacceptable toxicity. After detailed discussions, she was treated with belimumab, which controlled her SLE and allowed withdrawal of mycophenolate. Belimumab was continued throughout the pregnancy, leading to well-controlled SLE and uneventful course, albeit with the presence of mild Ebstein's anomaly in the baby. Conclusion: To our knowledge, this is the first case report of belimumab use throughout pregnancy for controlling active SLE. Data from the belimumab pregnancy registry would be useful to confirm our findings and to further assess safety of this agent for use in pregnancy.

KW - Belimumab

KW - Lupus

KW - Lupus nephritis

KW - Pregnancy

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84930680545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930680545&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2014.05.006

DO - 10.1016/j.semarthrit.2014.05.006

M3 - Article

VL - 44

SP - 195

EP - 197

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 2

ER -